Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers.

ABSTRACT: Recently, considerable progress has been achieved in cancer immunotherapy. Targeted immune checkpoint therapies have been established for several forms of cancers, which resulted in a tremendous positive impact on patient survival, even in more advanced tumor stages. With a better understanding of cellular responses to immune checkpoint therapies, it will soon be feasible to find targeted compounds which will make personalized medicine practicable. This is a great opportunity, but it also sets tremendous challenges on both the scientific and clinical aspects. Head and neck tumors evade immune surveillance through various mechanisms. They contain fewer lymphocytes (natural killer cells) than normal tissue with an accumulation of immunosuppressive regulatory T cells. Standard therapies for H

SUBMITTER: Ettl T 

PROVIDER: S-EPMC9599671 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature